Press release
Apr 28, 2016

Sosei Subsidiary Heptares Chief Scientific Officer and Co-Founder Dr Fiona Marshall Elected As A Fellow of The Academy of Medical Sciences


Tokyo, Japan –28 April 2016: Sosei Group Corporation (“Sosei”; TSE Mothers Index: 4565) today announces Heptares Therapeutics (“Heptares”), the wholly-owned subsidiary of Sosei, has reported that Dr Fiona Marshall, Chief Scientific Officer and co-founder, has been elected a Fellow of The Academy of Medical Sciences.

Fellows are drawn from laboratory science, clinical academic medicine, veterinary science, dentistry, medical and nursing care. Nominees are selected for their outstanding contribution to the advancement of medical science, or for the application of existing scientific knowledge or understanding in an innovative way.

Dr Marshall said: “I am honoured to join the Academy, which plays such an important role in promoting the excellence of UK medical science and in particular encourages partnerships between academia and industry – something I am very committed to.”

Malcolm Weir, Chief Executive Officer and Chairman of Heptares, added: “We are delighted for Fiona; this is very well deserved and justified recognition of her important contribution to basic academic research coupled to the discovery of new medicines, and towards the success of the U.K. biotechnology sector.”

Founded in 1998, the Academy of Medical Sciences is the independent body in the UK that represents the diverse spectrum of medical science – from basic research through clinical application to healthcare delivery. Its mission is to promote medical science and its translation into benefits for society.

Biography

Dr Marshall has more than 25 years’ experience, in the field of structure-based drug design and development with particular expertise in G protein-coupled receptors (GPCRs), the most important family of receptors in the human body for drug targeting. She is inventor of seven patents and author of over 80 peer-reviewed scientific papers in the area. Her work has contributed to the discovery of drugs in development for cancer, schizophrenia, Alzheimer’s disease and migraine.

Dr Marshall set up Heptares Therapeutics with Dr Malcolm Weir in 2006, building the company into one of the UK’s leading biotechnology companies prior to its acquisition in 2015 by Sosei Group, a Japan-based biopharmaceutical company. Following the acquisition, Dr Marshall became Executive VP and CSO of Sosei in addition to her current role as CSO of Heptares. She leads a team of 70 scientists at Heptares, which is pioneering a structure-based approach to GPCRs to create a broad pipeline of novel medicines with potential to transform the treatment of serious diseases. Heptares has established collaborations with Allergan, AstraZeneca, Kymab, MedImmune, MorphoSys, Pfizer and Teva.

Before Heptares, Dr Marshall worked in senior drug discovery roles at GlaxoWellcome / GlaxoSmithKline and Millennium Pharmaceuticals, and then spent several years as an independent consultant to a variety of venture capital and biotech companies.

Dr Marshall is on the Translation Advisory Group of the Francis Crick Institute and on the Scientific Advisory board of the Centre for Therapeutic Target Validation (CTTV). She is also on the Board of Trustees of Alzheimer’s Research UK (ARUK) and on the ARUK Drug Discovery Alliance Advisory Group.

Dr Marshall won the 2012 WISE Women of Outstanding Medicinal Achievement for Innovation and Entrepreneurship and received the Malcolm Campbell Memorial Prize 2015, awarded by the UK Royal Society of Chemistry’s Biological and  Chemistry Sector, in recognition of her contribution to GPCR drug discovery. She received a BSc in biochemistry from Bath University and a PhD in neuroscience from Cambridge University.  


 DOWNLOAD PDF